BMY Stock UPDATES Bristol-Myers Squibb Company (BMY) 58.19 11/02/2014
Post# of 273249
Posted On: 11/02/2014 8:53:27 PM
Bristol-Myers Squibb Company (BMY) 58.19 $BMY
Final Glance: Pharmaceuticals companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.18 (-0.65), AGN: 190.06 (+0.62), ACT: 242.74 (-0.47), BMY: 58.19 (-0.79)
Midday Glance: Pharmaceuticals companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Early Glance: Pharmaceuticals companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 190.06 (+0.62), MMM: 153.77 (+1.67), CMG: 638.00 (-1.68), BMY: 58.19 (-0.79)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.77 (+1.67), BIIB: 321.08 (+0.08), HON: 96.12 (+0.53), FB: 74.99 (+0.88), BMY: 58.19 (-0.79), MGM: 23.25 (+0.27), ATK: 116.96 (+6.77), YRCW: 21.44 (+3.24), UPS: 104.91 (+1.62), SLB: 98.66 (+1.04), CELG: 107.09 (+0.15), WPRT: 6.17 (+0.12), SBUX: 75.56 (-1.76), TTWO: 26.45 (+1.18), DO: 37.71 (-0.94), ETP: 64.43 (+0.41), GILD: 112.00 (-2.22), ARR: 3.96 (-0.01), CMG: 638.00 (-1.68), MPEL: 27.14 (+0.78), WNC: 10.30 (+0.81), CRL: 63.16 (+0.35), AAPL: 108.00 (+1.02), REGN: 393.72 (+0.92)
Lung cancer drug promising
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Bristol-Myers Squibb (BMY) reported good midstage trial results for its drug candidate Opdivo in advanced squamous-cell lung cancer, boosting its share price. The drugmaker said that a year after the treatment, 41% of patients were still alive;...
BMY: 58.19 (-0.79)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Most active New York Stock Exchange-traded stocks
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 41.88 (+0.48), AVP: 10.40 (+0.43), F: 14.09 (+0.14), GE: 25.81 (+0.14), ABX.TO: 13.38 (-0.37), ABX: 11.87 (-0.42), PFE: 29.95 (+0.11), BAC: 17.16 (+0.13), BMY: 58.19 (-0.79), RAD: 5.25 (+0.07), AA: 16.76 (+0.54), YRI.TO: 4.49 (-0.50), S: 5.93 (-0.07), TWTR: 41.47 (-0.33), AUY: 3.98 (-0.48)
Bristol-Myers Squibb (BMY) Stock Is Gaining on Positive Phase 2 Results
at The Street - Thu Oct 30, 1:30PM CDT
Bristol-Myers Squibb (BMY) shares are climbing after its lung cancer treatment showed positive phase 2 test results.
BMY: 58.19 (-0.79)
Big Pharma Solid Q3 Earnings Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - ZACKS - Thu Oct 30, 1:00PM CDT
Pharma ETFs have been surging over the past one week buoyed by solid earnings from big industry players.
IHE: 145.99 (-0.68), JNJ: 107.78 (+0.74), PPH: 63.38 (+0.22), PJP: 68.69 (+0.02), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
Business Wire - Thu Oct 30, 12:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.
BMY: 58.19 (-0.79)
Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers
PR Newswire - Thu Oct 30, 11:45AM CDT
Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed. Abilify is also one of the most preferred branded antipsychotics relative to other branded antipsychotics, according to surveyed managed care organization (MCO) medical director/pharmacy directors (MDs/PDs). The findings also reveal that the majority of surveyed psychiatrists perceive current antipsychotics to be only somewhat effective in reducing negative or cognitive symptoms of schizophrenia. Among emerging agents that were profiled, encenicline (Forum Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma) garnered the greatest expected patient share from surveyed psychiatrists, if the drug were to be reimbursed on a favorable tier for the treatment of cognitive impairment associated with schizophrenia (CIAS).
BMY: 58.19 (-0.79)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)
Final Glance: Pharmaceuticals companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.18 (-0.65), AGN: 190.06 (+0.62), ACT: 242.74 (-0.47), BMY: 58.19 (-0.79)
Midday Glance: Pharmaceuticals companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Early Glance: Pharmaceuticals companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 190.06 (+0.62), MMM: 153.77 (+1.67), CMG: 638.00 (-1.68), BMY: 58.19 (-0.79)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.77 (+1.67), BIIB: 321.08 (+0.08), HON: 96.12 (+0.53), FB: 74.99 (+0.88), BMY: 58.19 (-0.79), MGM: 23.25 (+0.27), ATK: 116.96 (+6.77), YRCW: 21.44 (+3.24), UPS: 104.91 (+1.62), SLB: 98.66 (+1.04), CELG: 107.09 (+0.15), WPRT: 6.17 (+0.12), SBUX: 75.56 (-1.76), TTWO: 26.45 (+1.18), DO: 37.71 (-0.94), ETP: 64.43 (+0.41), GILD: 112.00 (-2.22), ARR: 3.96 (-0.01), CMG: 638.00 (-1.68), MPEL: 27.14 (+0.78), WNC: 10.30 (+0.81), CRL: 63.16 (+0.35), AAPL: 108.00 (+1.02), REGN: 393.72 (+0.92)
Lung cancer drug promising
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Bristol-Myers Squibb (BMY) reported good midstage trial results for its drug candidate Opdivo in advanced squamous-cell lung cancer, boosting its share price. The drugmaker said that a year after the treatment, 41% of patients were still alive;...
BMY: 58.19 (-0.79)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Most active New York Stock Exchange-traded stocks
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 41.88 (+0.48), AVP: 10.40 (+0.43), F: 14.09 (+0.14), GE: 25.81 (+0.14), ABX.TO: 13.38 (-0.37), ABX: 11.87 (-0.42), PFE: 29.95 (+0.11), BAC: 17.16 (+0.13), BMY: 58.19 (-0.79), RAD: 5.25 (+0.07), AA: 16.76 (+0.54), YRI.TO: 4.49 (-0.50), S: 5.93 (-0.07), TWTR: 41.47 (-0.33), AUY: 3.98 (-0.48)
Bristol-Myers Squibb (BMY) Stock Is Gaining on Positive Phase 2 Results
at The Street - Thu Oct 30, 1:30PM CDT
Bristol-Myers Squibb (BMY) shares are climbing after its lung cancer treatment showed positive phase 2 test results.
BMY: 58.19 (-0.79)
Big Pharma Solid Q3 Earnings Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - ZACKS - Thu Oct 30, 1:00PM CDT
Pharma ETFs have been surging over the past one week buoyed by solid earnings from big industry players.
IHE: 145.99 (-0.68), JNJ: 107.78 (+0.74), PPH: 63.38 (+0.22), PJP: 68.69 (+0.02), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
Business Wire - Thu Oct 30, 12:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.
BMY: 58.19 (-0.79)
Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers
PR Newswire - Thu Oct 30, 11:45AM CDT
Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed. Abilify is also one of the most preferred branded antipsychotics relative to other branded antipsychotics, according to surveyed managed care organization (MCO) medical director/pharmacy directors (MDs/PDs). The findings also reveal that the majority of surveyed psychiatrists perceive current antipsychotics to be only somewhat effective in reducing negative or cognitive symptoms of schizophrenia. Among emerging agents that were profiled, encenicline (Forum Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma) garnered the greatest expected patient share from surveyed psychiatrists, if the drug were to be reimbursed on a favorable tier for the treatment of cognitive impairment associated with schizophrenia (CIAS).
BMY: 58.19 (-0.79)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)
(0)
(0)Scroll down for more posts ▼